Galmed Pharmaceuticals Ltd. (GLMD)
| Market Cap | 64.97M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -28.77M |
| Shares Out | 25.08M |
| EPS (ttm) | -1.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $2.59 |
| Previous Close | $2.65 |
| Change ($) | -0.06 |
| Change (%) | -2.26% |
| Day's Open | 2.54 |
| Day's Range | 2.51 - 2.70 |
| Day's Volume | 360,907 |
| 52-Week Range | 2.25 - 6.29 |
TEL AVIV, Israel, May 3, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory dis...
TEL AVIV, Israel, March 18, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the live...
TEL AVIV, Israel, March 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company today announced the treatment of the f...
TEL AVIV, Israel, March 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol...
TEL AVIV, Israel, Feb. 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory d...
TEL AVIV, Israel, Jan. 26, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory d...
TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory d...
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2020 Results - Earnings Call Transcript
TEL-AVIV, Israel and SHANGHAI, Sept. 10, 2020 /PRNewswire/ -- Gannex Pharma Co.
SHANGHAI and TEL-AVIV, Israel, Sept. 9, 2020 /PRNewswire/ -- Gannex Pharma Co.
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2020 Results - Earnings Call Transcript
TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
Galmed (GLMD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q1 2020 Results - Earnings Call Transcript
TEL AVIV, Israel, May 14, 2020 /PRNewswire/ --Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver t...
Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q4 2019 Results - Earnings Call Transcript
Top Ranked Momentum Stocks to Buy for December 4th
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q3 2019 Results - Earnings Call Transcript
While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2019 Results - Earnings Call Transcript
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2019 Results - Earnings Call Transcript
Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of 10.53% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
This off-the radar pick could be poised to be a huge winner. Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company.
Galmed Pharmaceuticals delivered earnings and revenue surprises of -58.33% and -100.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
About GLMD
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it eng... [Read more...]
| Industry Biotechnology | IPO Date Mar 13, 2014 |
| CEO Allen Baharaff | Employees 18 |
| Stock Exchange NASDAQ | Ticker Symbol GLMD |
Analyst Forecasts
According to 5 analysts, the average rating for GLMD stock is "Buy." The 12-month stock price forecast is 16.40, which is an increase of 533.20% from the latest price.